125 filings
6-K
GMAB
Genmab
21 Dec 20
Current report (foreign)
10:25am
6-K
GMAB
Genmab
15 Dec 20
Current report (foreign)
5:17pm
6-K
GMAB
Genmab
24 Nov 20
Genmab Announces Enapotamab Vedotin Update
11:59am
6-K
GMAB
Genmab
12 Nov 20
Current report (foreign)
9:54am
6-K
GMAB
Genmab
10 Nov 20
Capital Increase in Genmab as a Result of Employee Warrant Exercise
3:04pm
6-K
s2hzb
5 Nov 20
Genmab Announces Phase 3 Study Evaluating Epcoritamab in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
11:06am
6-K
j948i16lxyufbrp mgjq
4 Nov 20
Genmab Announces Financial Results for the First Nine Months of 2020
11:48am
6-K
gg4p9
21 Oct 20
Current report (foreign)
5:06pm
6-K
5hxhx3 axh
15 Oct 20
Current report (foreign)
11:09am
6-K
4pi65gisi9cdy5yanfu
14 Oct 20
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2020
4:54pm
6-K
a1gu7s5 qwyha
7 Oct 20
Current report (foreign)
5:15pm
6-K
tyyn8l4 c5i2y6tb8wf9
30 Sep 20
Current report (foreign)
2:06pm
6-K
478f2m7i5d0izz
30 Sep 20
Current report (foreign)
10:49am
6-K
xcay9 jla
30 Sep 20
Current report (foreign)
12:00am
6-K
5z26rm0i0jw 49
29 Sep 20
Capital Increase in Genmab as a Result of Employee Warrant Exercise
4:02pm
6-K
zm2zxug
22 Sep 20
Genmab Commences Binding Arbitration of Two Matters Under License Agreement with Janssen
5:14pm
6-K
v9y4h4q 7w
20 Aug 20
Current report (foreign)
5:29pm
6-K
bdot54xidhnftis24
20 Aug 20
Current report (foreign)
5:24pm
6-K
h8484t7z6awo 82xn
20 Aug 20
U.S. FDA Approves Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis
2:19pm
6-K
zb43nh
19 Aug 20
Current report (foreign)
10:59am